|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.12 - 17.25|
|52 Week Range||15.67 - 32.80|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||9.30|
|Forward Dividend & Yield||0.81 (5.05%)|
|1y Target Est||N/A|
Companies write off “goodwill” when the value of acquired assets declines. It happened at Kraft Heinz and GE. Keep an eye on Bayer and Cigna next.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
Zacks.com featured expert Kevin Matras highlights: Mallinckrodt Public, Bayer Aktiengesellschaft, United Natural Foods, Tutor Perini and G-III Apparel
Bayer said on Friday it would comply with a U.S. federal judge's order to enter mediation with a plaintiff who claims the company failed to warn against an alleged cancer risk from its Roundup weedkiller. Bayer has seen billions wiped off its market value since August, when a first U.S. jury found Bayer liable because Monsanto, acquired by Bayer for $63 billion last year, had not warned of the alleged risk from Roundup, which is based on active ingredient glyphosate. U.S. District Judge Vince Chhabria, who presided over the first two cases in federal court, said in a filing dated Thursday that Bayer and another plaintiff, Elaine Stevick, were ordered to start confidential mediation.
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
PARIS/LYON (Reuters) - A French court has ruled that Monsanto was liable for the sickness of a farmer who inhaled one of its weedkillers, in another legal setback for the Bayer-owned business over health claims. In the latest stage of a decade-long legal tussle, the appeals court in Lyon on Thursday found in favour of farmer Paul Francois' claim that Monsanto's Lasso weedkiller had made him sick and that the product's labelling had been inadequate. "Mr Francois justifiably concludes that the product, due to its inadequate labelling that did not respect applicable regulations, did not offer the level of safety he could legitimately expect," the court said in its ruling.
Vietnam's government said in a statement that the toxic level of herbicides containing glyphosate had long been of concern, in the latest display of global worries over the product's impact on human health. Glyphosate, the chemical contained in Bayer AG's best-selling weed killer Roundup, is the target of thousands of lawsuits in the United States alleging exposure to it causes cancer. Roundup, which Bayer acquired with its $63 billion purchase of Monsanto last year, was the first to contain glyphosate, the world's most widely used weed killer.
German chemical group Bayer said it was considering its legal options, including an appeal, after a French court ruled in favour of a farmer who blamed a weedkiller of Bayer's Monsanto unit for health problems. Thursday's ruling by an appeals court in Lyon in southeast France was the latest stage in a decade-long legal tussle between Monsanto and farmer Paul Francois, who says he fell ill after inhaling weedkiller Lasso in 2004.
Bayer's chief executive on Thursday acknowledged the German maker of pharmaceuticals and crop chemicals was facing massive challenges from a wave of lawsuits over an alleged carcinogenic effect of its Roundup weedkiller. You see it in our share price," CEO Werner Baumann said in a panel discussion at an academic business event in Cologne. Bayer has seen about 30 billion euros ($34 billion) wiped off its market value since August, when a U.S. jury found Bayer liable because Monsanto, acquired by Bayer for $63 billion last year, had not warned of weedkiller Roundup's alleged cancer risks.
Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).
One of Bayer's largest shareholders tore into the company's management on Wednesday for underestimating the legal risks of its takeover of Monsanto, setting the stage for a fiery annual general meeting after a 30 percent plunge in the shares. Bayer has seen about 30 billion euros ($34 billion) wiped off its market value since August, when a U.S. jury found Bayer liable because Monsanto had not warned of weedkiller Roundup's alleged cancer risks. There can be no talk of a successful takeover any more," Ingo Speich, the head of sustainability and corporate governance at Deka Investment, told Reuters.
Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).